AlzeCure Pharma AB (publ)

OM:ALZCUR Stock Report

Market Cap: kr108.7m

AlzeCure Pharma Future Growth

Future criteria checks 2/6

AlzeCure Pharma is forecast to grow earnings and revenue by 61.2% and 178.1% per annum respectively while EPS is expected to decline by 51.4% per annum.

Key information

61.2%

Earnings growth rate

-51.4%

EPS growth rate

Pharmaceuticals earnings growth48.3%
Revenue growth rate178.1%
Future return on equityn/a
Analyst coverage

Low

Last updated26 Apr 2024

Recent future growth updates

Recent updates

We Think AlzeCure Pharma (STO:ALZCUR) Can Afford To Drive Business Growth

Dec 02
We Think AlzeCure Pharma (STO:ALZCUR) Can Afford To Drive Business Growth

Companies Like AlzeCure Pharma (STO:ALZCUR) Can Afford To Invest In Growth

Jul 20
Companies Like AlzeCure Pharma (STO:ALZCUR) Can Afford To Invest In Growth

Will AlzeCure Pharma (STO:ALZCUR) Spend Its Cash Wisely?

Oct 12
Will AlzeCure Pharma (STO:ALZCUR) Spend Its Cash Wisely?

Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?

Jan 03
Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?

Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?

Jul 12
Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?

Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?

Mar 28
Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?

Need To Know: AlzeCure Pharma AB (publ) (STO:ALZCUR) Insiders Have Been Buying Shares

Feb 03
Need To Know: AlzeCure Pharma AB (publ) (STO:ALZCUR) Insiders Have Been Buying Shares

We're Not Very Worried About AlzeCure Pharma's (STO:ALZCUR) Cash Burn Rate

Dec 13
We're Not Very Worried About AlzeCure Pharma's (STO:ALZCUR) Cash Burn Rate

Earnings and Revenue Growth Forecasts

OM:ALZCUR - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20250-7-65-651
12/31/2024N/A-4617171
3/31/2024N/A-37-35-35N/A
12/31/2023N/A-3733N/A
9/30/2023N/A-38-40-40N/A
6/30/2023N/A-42-47-47N/A
3/31/2023N/A-53-14-14N/A
12/31/2022N/A-56-100-100N/A
9/30/2022N/A-68-70-70N/A
6/30/2022N/A-73-70-70N/A
3/31/2022N/A-67-110-110N/A
12/31/2021N/A-78-71-71N/A
9/30/2021N/A-73-70-70N/A
6/30/2021N/A-78-75-75N/A
3/31/2021N/A-81-78-78N/A
12/31/2020N/A-71-70-70N/A
9/30/2020N/A-69-64-63N/A
6/30/2020N/A-61-57-56N/A
3/31/2020N/A-53-50-49N/A
12/31/2019N/A-51-52-50N/A
9/30/2019N/A-48-50-49N/A
6/30/2019-2-40-44-42N/A
3/31/2019-1-38-40-39N/A
12/31/2018N/A-36-37-36N/A
9/30/20181-28-30-29N/A
12/31/20171-10N/A-8N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALZCUR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALZCUR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALZCUR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALZCUR's revenue (178.1% per year) is forecast to grow faster than the Swedish market (1.7% per year).

High Growth Revenue: ALZCUR's revenue (178.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ALZCUR's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.